An open label study of the effects of rituximab in neuromyelitis optica
Bruce Cree(University of California, San Francisco), Sara Lamb(University of California, San Francisco), Katherine A. Morgan(University of California, San Francisco), A. Chen(University of California, San Francisco), Emmanuelle Waubant(University of California, San Francisco), Claude P. Genain(University of California, San Francisco)
Cited by 646
Abstract
Eight patients with worsening neuromyelitis optica were treated with rituximab to achieve B cell depletion. Treatment was well tolerated. Six of eight patients were relapse free and median attack rate declined from 2.6 attacks/patient/year to 0 attacks/patient/year (p = 0.0078). Seven of eight patients experienced substantial recovery of neurologic function over 1 year of average follow-up. The pretreatment median Expanded Disability Status Scale score was 7.5, and at follow-up examination was 5.5 (p = 0.013).
Related Papers
No related papers found
Powered by citation graph analysis